Medical/Pharmaceuticals
Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial
SHANGHAI, May 11, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener (CB03), developed for the treatment of refractory epilepsy. CB03 is...
2022-05-12 08:00
2248
Asia's first molecular diagnostics company for women, INEX Innovate receives European CE-IVD Certification for its OvaCis(R) Rapid Test to detect cancer in ovarian cysts.
Revolutionary Ovarian Cancer Rapid Test Available Q4 2022 SINGAPORE, May 11, 2022 /PRNewswire/ -- Known as a pioneer in Asia's women's and fetal health industry,Singapore-based diagnostics developer, INEX Innovate has obtained a CE markfor its lead ovarian cancer product, the OvaCis® Rapid Test....
2022-05-11 22:00
3366
PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention
DAEJEON, South Korea, May 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that Dr.Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to par...
2022-05-11 20:00
3368
DetectedX Launches Radiology Online Learning Platform to the U.S. Market at SBI
The Intelligent Interactive Educational Technology from DetectedX has Shown a
34% Improvement in the Accuracy of Diagnosing Difficult Cases
SAVANNAH, Ga., May 11, 2022 /PRNewswire/ -- DetectedX
2022-05-11 20:00
3504
WORLD BRAIN DAY 2022 IS DEDICATED TO BRAIN HEALTH FOR ALL
LONDON, May 11, 2022 /PRNewswire/ -- On Friday, July 22, the World Federation of Neurology (WFN) is hosting the 9th Annual World Brain Day. WFN is pleased to announce that this year's theme isBrain Health for All. The all-encompassing theme aims to spark a universal effort that will share crucial...
2022-05-11 14:00
2554
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022
GAITHERSBURG, Md. and SUZHOU, China, May 11, 2022 /PRNewswire/ -- Sirnaomics
Ltd.
2022-05-11 13:05
3979
Prenetics and Artisan Acquisition Corp. Announce Shareholder Approval of Business Combination, To Begin Trading on Nasdaq on May 18 Under the Ticker "PRE"
* At Least US$260M of Proceeds from the Business Combination, Cash and Trade Receivables to Support Prenetics Growth * Closing of the Business Combination is Expected to Occur on May 18, 2022[1] * Prenetics Shares to Begin Trading on Nasdaq on May 18, 2022[1] Under Ticker "PRE" HONG KONG, Ma...
2022-05-11 09:00
3473
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functi...
2022-05-11 08:40
4427
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide
STOCKHOLM, Sweden, May 11, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company,announced on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally reported, cleaned and...
2022-05-11 06:42
2576
Global Cord Blood Corporation Announces Receipt of Blue Ocean Petition
HONG KONG, May 11, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company has received a copy ...
2022-05-11 04:16
3729
Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer
* Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR TKI, in advanced non-small cell lung cancer SEONGNAM, South Korea , May 10 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on deve...
2022-05-10 21:00
2633
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated tri...
2022-05-10 20:50
2901
Bora Pharmaceuticals acquires Eden Biologics CDMO Assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market TAIPEI, May 10, 2022 /PRNewswire/ -- Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the esta...
2022-05-10 17:53
5310
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company w...
2022-05-10 16:54
3492
OMRON Healthcare Unveils Long-term Corporate Vision, "Going for ZERO, Preventive Care for Health of Society"
- Aiming to Realize 3 Zeros: "Zero Cerebrovascular and Cardiovascular Events," "Zero Aggravation of Respiratory Diseases" and "Zero Restrictions on Daily Activities Due to Chronic Pain" - KYOTO, Japan, May 10, 2022 /PRNewswire/ -- In March 2022, OMRON Group announced a new long-term vision, "Sha...
2022-05-10 13:00
4111
Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse
* The Consortium jointly, through Aztiq II HoldCo, has completed the acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo * Róbert Wessman, Chairman and CEO of Alvogen and Founder of Aztiq Pharma ...
2022-05-10 11:00
3208
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
SHANGHAI, May 9, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, held a DEXTENZA Launch and Advisory Board Meeting recently inMacau, f...
2022-05-10 09:00
2255
Formus Labs, a Pioneering Developer of Orthopedic Surgery Planning Technology, Hires Ex-Johnson & Johnson Executive, Polly Teevan, To Lead Global Commercial Strategy
Having managed a nearly $1 billion business in the world's largest orthopedic market, Teevan brings 20+ years of experience to help Formus improve patient lives AUCKLAND, New Zealand, May 10, 2022 /PRNewswire/ -- Formus Labs, creator of the world's first fully-automated 3D planner for joint repl...
2022-05-10 03:00
2497
iNtRON Biotechnology, Inc., Launches New Website
It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- The parent company of iNtODEWORLD, Inc., iNtRON Biotechnology, Inc., ("iNtRON" or "Company") is ...
2022-05-09 21:00
3102
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant * Review of the monoclonal antibody combination therapy is underway by the U.S. Food and Drug Administration (FDA) for Emergency Use Auth...
2022-05-09 19:46
3905
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
25933
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
14837
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
14355
OceanaGold Reports Third Quarter 2026 Results
2026-11-05 06:52
14177